Illumina sequencing and array products facilitate clinical cancer research by providing expert-defined gene content, accurate data, and simple analysis and reporting options.
Featured Sequencing Research Panels
AmpliSeq for Illumina Sequencing Panels—Optimized for clinical cancer research applications and available as predesigned or made-to-order panels; use with
targets ranging from a few to hundreds of genes in a single run.
TruSight RNA Fusion—This targeted RNA sequencing research panel is a cost-effective solution to detect gene fusions in
multiple cancer types, regardless of origin.
TruSight Tumor 170—Comprehensive research panel detects single-nucleotide variants (SNVs), amplifications, and fusions
that contribute to solid tumor progression.
TruSight Oncology UMI Reagents—The TruSight Oncology UMI Reagents and UMI Error Correction App reduce error rates in samples to ≤0.007%, enabling the detection of low frequency variants.
TruSight RNA Pan-Cancer—Targeting 1385 oncology genes for gene expression, variant and fusion detection studies in
all RNA sample types including FFPE.
TruSight Tumor 15—Focused research panel to assess relevant solid tumor somatic variants in a simple, sample-to-data
Infinium OncoArray-500K BeadChip—An expert-designed, high-density array for researching cancer predisposition and risk. Contains ~500,000 genome-wide SNPs, plus putative SNPs associated with breast, colorectal, lung, ovarian, and prostate cancer.